Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that RET oncogenic variants status confers therapeutic sensitivity to Selpercatinib in patients with Medullary Thyroid Cancer.
This statement is based on a regulatory approval from the Health Canada:
RETEVMO (selpercatinib) is indicated as monotherapy for the treatment of RET-mutant medullary thyroid cancer (MTC) in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease.